NDA 050682 · Recordati Rare
Cosmegen
Dactinomycin · Injection
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 15, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Dec 10, 1964
Approved uses
3
Original approval plus efficacy supplements
Registered trials
70
32 Phase 3, 17 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 15, 2018 Supplement 34 · Efficacy LabelLetter
- Aug 15, 2018 Supplement 33 · Efficacy LabelLetter
- Dec 10, 1964 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- COSMEGEN · DACTINOMYCIN 0.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dactinomycin" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002611 · 3,031 participants · Start Jul 1995 · Primary completion Jun 2002
Drug: dactinomycin; filgrastim and 4 more · For: Kidney Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04625907 · 1,672 participants (planned) · Start Sep 17, 2020 · Primary completion Jun 2030
Drug: Irinotecan; Actinomycin D and 7 more · For: Rhabdomyosarcoma
Sites: Brisbane, Australia; Camperdown, Australia; Clayton, Australia · 128 sites in all
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT06401330 · 1,656 participants (planned) · Start Apr 15, 2025 · Primary completion Feb 13, 2031
Drug: Carboplatin; Cyclophosphamide and 5 more · For: Stage I Mixed Cell Type Kidney Wilms Tumor; Stage II Mixed Cell Type Kidney Wilms Tumor; Stage III Mixed Cell Type Kidney Wilms Tumor and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 169 sites in all
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaPivotal-lookingStatus unknown
University of LeicesterAcademic, hospital or other
NCT00020566 · 1,200 participants (planned) · Start Feb 2001 · Primary completion Dec 2011
Drug: dactinomycin; busulfan and 5 more · For: Sarcoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 103 sites in all
Children's Oncology GroupResearch network
NCT00352534 · 808 participants · Start Nov 6, 2006 · Primary completion Dec 31, 2014
Drug: Dactinomycin; Doxorubicin Hydrochloride and 1 more · For: Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 240 sites in all
- Combination Chemotherapy in Treating Patients With Previously Untreated RhabdomyosarcomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00003958 · 702 participants · Start Sep 2002 · Primary completion Oct 2007
Drug: dactinomycin; vincristine sulfate and 4 more · For: Adult Malignant Mesenchymoma; Adult Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma and 8 more
Sites: Arcadia, California
- Combination Chemotherapy in Treating Young Patients With Nonmetastatic RhabdomyosarcomaPivotal-lookingStatus unknown
European Paediatric Soft Tissue Sarcoma Study GroupAcademic, hospital or other
NCT00379457 · 600 participants (planned) · Start Jun 2006 · Primary completion May 2011
Drug: dactinomycin; carboplatin and 7 more · For: Sarcoma
Sites: Vienna, Austria; Brussels, Belgium; Copenhagen, Denmark · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: COsmegen* (Dactinomycin*) · HCPCS J9120
2024 spending
$137K
Beneficiaries
22
81 claims
Per beneficiary
$6,241
2024 ASP limit $474.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $430,032 |
| 2021 | $331,574 |
| 2022 | $138,230 |
| 2023 | $148,292 |
| 2024 | $137,313 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Dix DB, Seibel NL, Chi YY, et al. · J Clin Oncol 2018 · Clinical Trial, Research Support, N.I.H., Extramural
- Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, et al. · J Clin Oncol 2009 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Intrathecal chemotherapy: potential for medication error.
Gilbar PJ · Cancer Nurs 2014 · Systematic Review
- Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE, Krailo MD, Tarbell NJ, et al. · N Engl J Med 2003 · Clinical Trial, Multicenter Study
- Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.
Alazzam M, Tidy J, Osborne R, et al. · Cochrane Database Syst Rev 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG).
Sudour-Bonnange H, van Tinteren H, Ramírez-Villar GL, et al. · Br J Cancer 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.